BiotechTube

vatreptacog alfa (activated) + eptacog alfa (activated)

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Congenital Bleeding Disorder

Conditions

Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

Trial Timeline

Jul 1, 2011 → Aug 1, 2012

NCT ID
NCT01392547

About vatreptacog alfa (activated) + eptacog alfa (activated)

vatreptacog alfa (activated) + eptacog alfa (activated) is a phase 3 stage product being developed by Novo Nordisk for Congenital Bleeding Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01392547. Target conditions include Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors.

What happened to similar drugs?

4 of 20 similar drugs in Congenital Bleeding Disorder were approved

Approved (4) Terminated (0) Active (16)
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
🔄turoctocog alfa pegolNovo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01392547Phase 3Completed

Competing Products

20 competing products in Congenital Bleeding Disorder

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
EDIT-101Editas MedicinePhase 1/2
18
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
KW-3357Kyowa KirinPhase 1
29
Pasireotide 0.6Mg Solution for Injection + Saline SolutionNovartisPhase 2
27
Sandostatine LPNovartisPhase 2
35
mycophenolate mofetilRochePhase 1
29
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
turoctocog alfa pegolNovo NordiskPhase 3
40
recombinant factor XIIINovo NordiskPre-clinical
26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
29
Advate® + turoctocog alfaNovo NordiskPhase 1
29